Navigation Links
Selexis Announces Expansion of R&D License Agreement with Amgen
Date:2/20/2013

GENEVA, Feb. 20, 2013 /PRNewswire/ -- Selexis SA, a global life sciences company for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins, announced today that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.  Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D. 

(Logo: http://photos.prnewswire.com/prnh/20120627/LA31604LOGO)

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable," said Igor Fisch , Ph.D., President and CEO of Selexis. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently.  This current agreement is built on the long-standing relationship between our two companies since 2004." 

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,700 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.

For more information, visit http://www.selexis.com

Media Inquires
Robert Meister
Selexis SA
Tel: +1 (602) 953-1716
Email: robert.meister@selexis.com

 


'/>"/>
SOURCE Selexis SA
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Selexis Lubris Partnership Advances Difficult-to-Express Protein Towards Clinic
2. Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call
3. Incisive Surgical Announces Sale Of One-Millionth INSORB Stapler
4. BioMed Realty Trust Announces Exercise Of Option To Purchase Additional Shares Of Common Stock
5. UBM Canon, the Global Authority on the MedTech Industry, Announces Senior Editor for MD+DI (Medical Device & Diagnostic Industry)
6. Silver Lining Textiles, Manufacturers of Anti-microbial Under Scrub Garments for the Healthcare Industry, Announces Their Availability Through Amazon.com
7. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
8. Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID
9. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
10. Vomaris Announces initiation of study with Walter Reed National Military Medical Centers Combat Wound Initiative
11. Emergency Nurses Association Announces Corporate Sponsors for Leadership Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... DUBLIN , Jan 18, 2017 Research ... Nausea and Vomiting Drugs Market 2017-2021" report to their offering. ... The global ... the period 2017-2021. Global Thoracic Surgery Market 2017-2021, ... from industry experts. The report covers the market landscape and its ...
(Date:1/18/2017)... SHANGHAI , Jan. 18, 2017 In ... of revolution, which is where the Upgrade of ... year of the 13th Five-Year Plan for Economic and Social ... (the 13th Five-Year Plan), and the state council of ... the "13th Five-Year" national strategic emerging industry development plan, identifying ...
(Date:1/18/2017)... Ximbio, a non-profit online one-stop-shop for the global ... first North American headquarters in Kendall Square, Cambridge, ... ... launch in October 2014 as a business unit of UK- ... the foundation Cancer Research UK. Ximbio.com allows scientists ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy Associates, Inc., ... Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael J. Hennessy, ... biosimilars through thought leader interaction in, live video and interactive digital platforms. , ...
(Date:1/17/2017)... ... January 17, 2017 , ... January is National Stalking Awareness Month (NSAM), now ... in the corners and commit the crime of stalking, a very real danger to many ... often overlooked factor in stalking and other crimes. , “Stalking: know it. Name it. Stop ...
(Date:1/17/2017)... ... 17, 2017 , ... Today, to help those who are ... uplifting interview with medical expert and prolific author, Dr. Bernie Siegel. ... times, Dr. Bernie Siegel energizes listeners to live life with intrigue, magic and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... a new 21st century approach to infusing high speed technology into the fabric ... exclusively dedicated to the advancement of healthcare and wellness in a yet-to-be-named, health ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... will lecture to primary eye care practitioners on the latest breakthroughs in the ... 13th Semi-Annual Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, ...
Breaking Medicine News(10 mins):